Am J Cardiol: 用多根动脉搭桥,可降低再次血管重建风险!美国Meta分析

2020-06-29 xujing 中国循环杂志

近期一项Meta分析显示,多支动脉搭桥术与单支动脉搭桥术相比,没有生存优势,胸骨伤口并发症的发生率更高,但降低了再次血管重建和卒中风险。

近期一项Meta分析显示,多支动脉搭桥术与单支动脉搭桥术相比,没有生存优势,胸骨伤口并发症的发生率更高,但降低了再次血管重建和卒中风险。

阜外医院也有研究发现,对于合并糖尿病的冠状动脉多支病变患者,术后平均近5年时,造影或CT复查结果显示,桡动脉桥血管通畅率为83.6%,显著高于大隐静脉桥血管的62.3%。

研究人员评估了10项比较单支动脉搭桥术与多支动脉搭桥术的随机对照试验。纳入Meta分析的患者6392例,平均年龄为56-75岁,平均随访4年。

在全因死亡率、心脏死亡率、心肌梗死、大出血方面,单支动脉搭桥术与多支动脉搭桥术无差异。

排除其中一项混杂研究后,多支动脉搭桥术的再次血运重建风险低于单支动脉搭桥术(RR= 0.63),脑卒中发生率也低于单支动脉搭桥术(2.9% vs. 3.9%,RR =0.74)。

多支动脉搭桥术的胸骨创伤并发症发生率高于单支动脉搭桥术(2.9% vs. 1.7%,RR=1.75)。

研究者认为,血管重建和卒中风险的优势可能会被胸骨伤口并发症的高发病率所抵消。

原始出处:Khalid Changalm, Saqib Masroor, Ahmed Elzanaty. et al. Meta-analysis Comparing Multiple Arterial Grafts versus Single Arterial Graft for Coronary-Artery Bypass Grafting Bypass Grafting. Am J Cardiol.Published:June 15, 2020. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782085, encodeId=4c5a1e8208586, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 05 16:37:44 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663966, encodeId=3fc4166396655, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 05 04:37:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888165, encodeId=dd70188816562, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Jun 13 17:37:44 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899415, encodeId=86ed8994150f, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLWROGia7f3ficvom5MMQRnYVzLg9ibA7gJvvUeGDuylYP3de77n3NvQucKFsdz5F2npWEA3arQwxrKQ/132, createdBy=09ed2341770, createdName=心之方向, createdTime=Mon Nov 16 00:03:55 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896691, encodeId=a56718966919c, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 26 21:37:44 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782085, encodeId=4c5a1e8208586, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 05 16:37:44 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663966, encodeId=3fc4166396655, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 05 04:37:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888165, encodeId=dd70188816562, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Jun 13 17:37:44 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899415, encodeId=86ed8994150f, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLWROGia7f3ficvom5MMQRnYVzLg9ibA7gJvvUeGDuylYP3de77n3NvQucKFsdz5F2npWEA3arQwxrKQ/132, createdBy=09ed2341770, createdName=心之方向, createdTime=Mon Nov 16 00:03:55 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896691, encodeId=a56718966919c, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 26 21:37:44 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782085, encodeId=4c5a1e8208586, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 05 16:37:44 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663966, encodeId=3fc4166396655, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 05 04:37:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888165, encodeId=dd70188816562, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Jun 13 17:37:44 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899415, encodeId=86ed8994150f, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLWROGia7f3ficvom5MMQRnYVzLg9ibA7gJvvUeGDuylYP3de77n3NvQucKFsdz5F2npWEA3arQwxrKQ/132, createdBy=09ed2341770, createdName=心之方向, createdTime=Mon Nov 16 00:03:55 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896691, encodeId=a56718966919c, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 26 21:37:44 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
    2021-06-13 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782085, encodeId=4c5a1e8208586, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 05 16:37:44 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663966, encodeId=3fc4166396655, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 05 04:37:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888165, encodeId=dd70188816562, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Jun 13 17:37:44 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899415, encodeId=86ed8994150f, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLWROGia7f3ficvom5MMQRnYVzLg9ibA7gJvvUeGDuylYP3de77n3NvQucKFsdz5F2npWEA3arQwxrKQ/132, createdBy=09ed2341770, createdName=心之方向, createdTime=Mon Nov 16 00:03:55 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896691, encodeId=a56718966919c, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 26 21:37:44 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
    2020-11-16 心之方向

    值得借鉴

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1782085, encodeId=4c5a1e8208586, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 05 16:37:44 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663966, encodeId=3fc4166396655, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 05 04:37:44 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888165, encodeId=dd70188816562, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Jun 13 17:37:44 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899415, encodeId=86ed8994150f, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLWROGia7f3ficvom5MMQRnYVzLg9ibA7gJvvUeGDuylYP3de77n3NvQucKFsdz5F2npWEA3arQwxrKQ/132, createdBy=09ed2341770, createdName=心之方向, createdTime=Mon Nov 16 00:03:55 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896691, encodeId=a56718966919c, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 26 21:37:44 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
    2020-07-26 一闲

相关资讯

DCR:体弱患者接受机器人手术治疗结肠癌会导致更严重的术后并发症的发生

目前微创手术越来越受到医生和患者的青睐,但是,人们对机器人手术对某些特定人群的影响(如体弱的患者)了解甚少。本项研究的目的是探究体弱患者与微创手术方法与结肠癌手术之间的关联。

Sci Rep:开胸手术中限制性液体管理与复合并发症的发生率更高相关

与更严格的液体管理相比,就复合并发症而言,术中净输液速度保持在4-5ml.kg-1.h-1与开胸手术的结局更好相关。

胃造瘘术后并发症的观察和处理

经皮内镜下胃造瘘(percutaneous endoscopic gastrostomy, PEG )是肠内营养的实施手段之一,主要适用于因需要长期接受营养支持的患者或无法经口进食者。

Eur Arch Otorhinolaryngol:耳蜗移植的手术并发症分析

尽管耳蜗移植技术已经很先进,但是相关的并发症发生率还是很高。最近,有研究人员使用紧密随访的一个大的患者群体数据进行了案例分析,鉴定了与耳蜗移植相关的并发症,并展现了他们使用的手术经验和技术,以遵循手术

Clin Otolaryngol:与嗜酸性慢性鼻窦炎相关的并发症分析

嗜酸性慢性鼻窦炎(ECRS)是CRS的一种组织学亚型,并且治疗难度更大。与非ECRS患者相比,患有ECRS的患者症状更重,且鼻窦手术后治疗效果差。手术前ECRS的组织病理学和生物标志物评估通常是不可用

Sci Rep:一种可以预测TAVI结局的计算框架

这项研究表明,计算工具有助于TAVI的安全规划和扩展。